Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine plus routine treatment for ICU-hospitalized patients with COVID-19
IRCT20210913052467N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- May 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of colchicine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Disease severity by APACHE II Score. Started May 2022; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210913052467N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210913052467N1.